Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial

• Autori principali: Jingjun Qiu (Autore), Yunkai Yang (Autore), Lirong Huang (Autore), Ling Wang (Autore), Zhiwei Jiang (Autore), Jian Gong (Autore), Wei Wang (Autore), Hongyan Wang (Autore), Shaohong Guo (Autore), Chanjuan Li (Autore), Shuyuan Wei (Autore), Zhaojun Mo (Autore), Jielai Xia (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2017-06-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background: The type 2 component of the oral poliovirus vaccine is targeted for global withdrawal through a switch from the trivalent oral poliovirus vaccine (tOPV) to a bivalent oral poliovirus vaccine (bOPV). The switch is intended to prevent paralytic polio caused by circulating vaccine-derived p...